Literature DB >> 9843958

Apoprotein B100 has a prolonged interaction with the translocon during which its lipidation and translocation change from dependence on the microsomal triglyceride transfer protein to independence.

D M Mitchell1, M Zhou, R Pariyarath, H Wang, J D Aitchison, H N Ginsberg, E A Fisher.   

Abstract

When lipid synthesis is limited in HepG2 cells, apoprotein B100 (apoB100) is not secreted but rapidly degraded by the ubiquitin-proteasome pathway. To investigate apoB100 biosynthesis and secretion further, the physical and functional states of apoB100 destined for either degradation or lipoprotein assembly were studied under conditions in which lipid synthesis, proteasomal activity, and microsomal triglyceride transfer protein (MTP) lipid-transfer activity were varied. Cells were pretreated with a proteasomal inhibitor (which remained with the cells throughout the experiment) and radiolabeled for 15 min. During the chase period, labeled apoB100 remained associated with the microsomes. Furthermore, by crosslinking sec61beta to apoB100, we showed that apoB100 remained close to the translocon at the same time apoB100-ubiquitin conjugates could be detected. When lipid synthesis and lipoprotein assembly/secretion were stimulated by adding oleic acid (OA) to the chase medium, apoB100 was deubiquitinated, and its interaction with sec61beta was disrupted, signifying completion of translocation concomitant with the formation of lipoprotein particles. MTP participates in apoB100 translocation and lipoprotein assembly. In the presence of OA, when MTP lipid-transfer activity was inhibited at the end of pulse labeling, apoB100 secretion was abolished. In contrast, when the labeled apoB100 was allowed to accumulate in the cell for 60 min before adding OA and the inhibitor, apoB100 lipidation and secretion were no longer impaired. Overall, the data imply that during most of its association with the endoplasmic reticulum, apoB100 is close to or within the translocon and is accessible to both the ubiquitin-proteasome and lipoprotein-assembly pathways. Furthermore, MTP lipid-transfer activity seems to be necessary only for early translocation and lipidation events.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9843958      PMCID: PMC24518          DOI: 10.1073/pnas.95.25.14733

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  55 in total

1.  In vivo assembly of the proteasomal complexes, implications for antigen processing.

Authors:  Y Yang; K Früh; K Ahn; P A Peterson
Journal:  J Biol Chem       Date:  1995-11-17       Impact factor: 5.157

2.  Regulated Co-translational ubiquitination of apolipoprotein B100. A new paradigm for proteasomal degradation of a secretory protein.

Authors:  M Zhou; E A Fisher; H N Ginsberg
Journal:  J Biol Chem       Date:  1998-09-18       Impact factor: 5.157

3.  Apoprotein B100, an inefficiently translocated secretory protein, is bound to the cytosolic chaperone, heat shock protein 70.

Authors:  M Zhou; X Wu; L S Huang; H N Ginsberg
Journal:  J Biol Chem       Date:  1995-10-20       Impact factor: 5.157

4.  Degradation of CFTR by the ubiquitin-proteasome pathway.

Authors:  C L Ward; S Omura; R R Kopito
Journal:  Cell       Date:  1995-10-06       Impact factor: 41.582

5.  Multiple proteolytic systems, including the proteasome, contribute to CFTR processing.

Authors:  T J Jensen; M A Loo; S Pind; D B Williams; A L Goldberg; J R Riordan
Journal:  Cell       Date:  1995-10-06       Impact factor: 41.582

6.  Studies on the assembly of apolipoprotein B-100- and B-48-containing very low density lipoproteins in McA-RH7777 cells.

Authors:  J Borén; S Rustaeus; S O Olofsson
Journal:  J Biol Chem       Date:  1994-10-14       Impact factor: 5.157

7.  apoB-100 has a pentapartite structure composed of three amphipathic alpha-helical domains alternating with two amphipathic beta-strand domains. Detection by the computer program LOCATE.

Authors:  J P Segrest; M K Jones; V K Mishra; G M Anantharamaiah; D W Garber
Journal:  Arterioscler Thromb       Date:  1994-10

8.  Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin.

Authors:  G Fenteany; R F Standaert; W S Lane; S Choi; E J Corey; S L Schreiber
Journal:  Science       Date:  1995-05-05       Impact factor: 47.728

9.  In HepG2 cells, translocation, not degradation, determines the fate of the de novo synthesized apolipoprotein B.

Authors:  J A Bonnardel; R A Davis
Journal:  J Biol Chem       Date:  1995-12-01       Impact factor: 5.157

10.  Misfolded major histocompatibility complex class I molecules accumulate in an expanded ER-Golgi intermediate compartment.

Authors:  G Raposo; H M van Santen; R Leijendekker; H J Geuze; H L Ploegh
Journal:  J Cell Biol       Date:  1995-12       Impact factor: 10.539

View more
  29 in total

1.  Impaired-inactivation of FoxO1 contributes to glucose-mediated increases in serum very low-density lipoprotein.

Authors:  Ke Wu; David Cappel; Melissa Martinez; John M Stafford
Journal:  Endocrinology       Date:  2010-05-25       Impact factor: 4.736

2.  Ubiquitination regulates the assembly of VLDL in HepG2 cells and is the committing step of the apoB-100 ERAD pathway.

Authors:  Eric A Fisher; Neeraj A Khanna; Roger S McLeod
Journal:  J Lipid Res       Date:  2011-03-18       Impact factor: 5.922

Review 3.  Hepatic regulation of apolipoprotein B.

Authors:  Rita Kohen Avramoglu; Khosrow Adeli
Journal:  Rev Endocr Metab Disord       Date:  2004-12       Impact factor: 6.514

Review 4.  Can modulators of apolipoproteinB biogenesis serve as an alternate target for cholesterol-lowering drugs?

Authors:  Lynley M Doonan; Edward A Fisher; Jeffrey L Brodsky
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-04-06       Impact factor: 4.698

5.  The role of the LDL receptor in apolipoprotein B secretion.

Authors:  J Twisk; D L Gillian-Daniel; A Tebon; L Wang; P H Barrett; A D Attie
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

6.  Apolipoprotein B-containing lipoprotein assembly in microsomal triglyceride transfer protein-deficient McA-RH7777 cells.

Authors:  Yanwen Liu; Medha Manchekar; Zhihuan Sun; Paul E Richardson; Nassrin Dashti
Journal:  J Lipid Res       Date:  2010-02-24       Impact factor: 5.922

7.  The Hsp110 molecular chaperone stabilizes apolipoprotein B from endoplasmic reticulum-associated degradation (ERAD).

Authors:  Stacy L Hrizo; Viktoria Gusarova; David M Habiel; Jennifer L Goeckeler; Edward A Fisher; Jeffrey L Brodsky
Journal:  J Biol Chem       Date:  2007-09-06       Impact factor: 5.157

Review 8.  The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism.

Authors:  Henry N Ginsberg; Edward A Fisher
Journal:  J Lipid Res       Date:  2008-12-02       Impact factor: 5.922

Review 9.  The many intersecting pathways underlying apolipoprotein B secretion and degradation.

Authors:  Jeffrey L Brodsky; Edward A Fisher
Journal:  Trends Endocrinol Metab       Date:  2008-08-06       Impact factor: 12.015

10.  Central nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion.

Authors:  John M Stafford; Fang Yu; Richard Printz; Alyssa H Hasty; Larry L Swift; Kevin D Niswender
Journal:  Diabetes       Date:  2008-03-10       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.